Biofrontera | 8-K: FY2025 Q3 Revenue Misses Estimate at USD 6.988 M

LB filings
2025.11.13 13:33
portai
I'm PortAI, I can summarize articles.

Revenue: As of FY2025 Q3, the actual value is USD 6.988 M, missing the estimate of USD 7 M.

EPS: As of FY2025 Q3, the actual value is USD -0.62, missing the estimate of USD -0.58.

EBIT: As of FY2025 Q3, the actual value is USD -6.532 M.

Segment Revenue

  • Total revenues for the third quarter of 2025 were $7.0 million, a decrease from $9.0 million in the third quarter of 2024, reflecting a 22% year-over-year decline due to advanced purchases ahead of the October 2024 price increase.
  • Revenues for the first nine months of 2025 were stable at $24.6 million compared to $24.8 million for the same period in 2024.

Operational Metrics

  • Operating expenses decreased by 5% year-over-year in the third quarter of 2025 compared to the third quarter of 2024.
  • The net loss for the third quarter of 2025 was $6.6 million, compared to a net loss of $5.7 million for the prior-year quarter.
  • Adjusted EBITDA for the third quarter of 2025 was - $6.0 million compared to - $4.6 million for the third quarter of 2024.

Cash Flow

  • Cash balance was $3.4 million as of September 30, 2025.

Unique Metrics

  • The company completed the purchase of all Ameluz and RhodoLED US Assets from Biofrontera AG, reducing the payment rate to 12%–15% of U.S. net sales from 25%–35%.
  • The divestiture of Xepi antibiotic cream to Pelthos Pharmaceuticals was announced for $3 million at closing, $1 million upon commercial availability, and up to $6 million in milestone payments.

Outlook / Guidance

  • Biofrontera Inc. anticipates substantial fourth quarter and year-over-year annual revenue growth, supported by growing demand for Ameluz-PDT treatment.
  • The company is encouraged by the potential of its clinical studies to gain FDA approval for the use of Ameluz to treat actinic keratoses on the entire body and potentially extend to superficial basal cell carcinoma and acne vulgaris.
  • The acquisition of U.S. rights, approvals, and patents for Ameluz and RhodoLED lamps is expected to enhance gross margins and strengthen long-term profitability.
Source: LB filings The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.